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T
he thriving fi  eld of adult stem cells 
and its burgeoning therapeutic 
promise owe a big tip of the hat to 
Irv Weissman, who in the late ’80s isolated 
the fi  rst class of these pluripotent cells—the 
mouse hematopoeitic stem cell (1). Not long 
afterwards, he identifi  ed its human counter-
part (2) and then began determining the 
environmental cells in the bone marrow 
(3, 4) and thymus (5, 6) that are necessary 
to support developing blood cell lineages. 
Stem cell and cell lineage research is a criti-
cal component of his Stanford and Hopkins 
Marine Station laboratories as well as 
several companies he has helped found.
Not surprisingly, Weissman has been 
far from silent in political debates in this 
arena. After the Bush administration’s ban 
on NIH funding for research using newly 
derived human embryonic stem cell lines, 
Weissman was instrumental in the writing 
and passage of California’s Proposition 71, 
which protected the research as a state 
right and allocated three billion dollars in 
funding over 10 years. Weissman recently 
took time to discuss his past and future 
infl  uence in the fi  eld.
MONTANA TRANSPLANTATION
Where did you grow up?
I grew up in Great Falls, Montana, and I still 
get back there a lot. I started in a laboratory 
when I was 16 with Ernst 
Eichwald, a pathologist 
who was editor of the 
journal Transplantation. 
His laboratory now in-
cludes fi   ve PIs and is 
called the McLaughlin 
Research Institute. I’m 
head of the scientifi  c ad-
visory board, so I spend a 
fair amount of time going 
back and forth.
How did you get interested in working 
in the laboratory so young?
When I was 10, I read a book called Mi-
crobe Hunters about the life of scientists. 
I went and talked to Ernst because I heard 
he had mice that I might be able to take 
care of. After the fi  rst week, he gave me a 
paper to read that was totally impossible. It 
was about “histocompatibility genes.” If it 
had said “tissue transplantation genes,” it 
would have been easy to understand. Of 
course, now I know that people write and 
speak like this all the time to make our fi  eld 
obscure and diffi  cult to teach and learn.
When did you become fascinated by 
stem cells?
I was fascinated from the very beginning 
by a paper from Billingham, Brent, and 
Medawar, who induced transplantation tol-
erance in fetal mice. That meant to me that 
the immune system was maturing during a 
mouse’s fetal or early neonatal life, and I 
wanted to better fi  nd out when.
When I was in medical school, 
Jacques Miller showed that if you removed 
the thymus from newborn mice, they 
couldn’t reject grafts, so I began tapping 
into cellular lineages in the thymus. I want-
ed to know if there really was such a thing 
as a common lymphocyte progenitor.
How did you succeed in identifying the 
ﬁ  rst stem cell population?
I had found that a cell that had a B cell 
surface marker couldn’t make a clone of T 
cells, not surprisingly. But it couldn’t make 
a clone of B cells either. 
That meant that the pre-
cursor for a B lym-
phocyte didn’t have a B 
cell marker on its surface. 
It struck me that it also 
wouldn’t have a T cell, 
macrophage, or red blood 
cell marker—they would 
all be absent from a cell 
that could make at least B 
and T cells.
I remember at that moment think-
ing, “I’m not working on lymphocyte de-
velopment; I’m working on stem cells.” 
Then very rapidly, we isolated the mouse 
blood–forming stem cells. But I didn’t 
set out to do it.
THE HISTORY OF 
HISTOCOMPATIBILITY
What’s the focus in your Hopkins Marine 
Station laboratory?
There, we found the most primitive chor-
date that can make an immune response. 
It’s called Botryllus schlosseri, an ocean 
creature that metamorphoses during devel-
opment into an invertebrate by losing all 
of its chordate characteristics.
When two individuals or colonies 
abut in the ocean, they send blood vessels 
into the other and they either fuse or un-
dergo an immune rejection. We showed that 
this choice was determined by a single gene 
locus with over 100 alleles. Generally, only 
siblings share the right alleles to fuse.
This gene has four homologues in 
humans, one of which is an activating 
ligand for receptors on natural killer cells. 
So this probably was the beginning of the 
natural killer cell system, which recognizes 
self and kills anything that’s not self.
And some of them are markers that 
we now know are on stem cells. So I think 
we’re looking at the evolution of stem cell 
systems, caught mid-phylogeny in this 
animal that’s a vertebrate during fetal life 
and an invertebrate for the rest of its life.
What else has this primitive organism 
taught you about the immune system?
This animal uses a budding process to 
build new bodies. We showed in the ’90s 
that the cells of a developing body could 
come from both the budding animal and a 
fused sibling. But germ line cells were 
competing ruthlessly; they all come from 
A force behind both the science and politics of stem cell biology, 
Weissman now strives to translate his successes to the clinic.
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only one of the fused colonies. We isolat-
ed the stem cell subset and showed that 
those from a winner colony beat out those 
from another when they’re both injected 
into the bloodstream of a host.
Almost certainly then, the immune 
rejection mechanism is a way to limit germ
line stem cell competition and parasitism 
to your sibling. You might end up being the 
loser, but at least half of your genes will 
be carried to the next generation, because 
your sibling has half of your genes.
RIGHT TO RESEARCH
As a force behind Proposition 71, how did 
you convince politicians of the importance 
of embryonic stem cell research?
I simply explained that if you have a genetic 
disease, you might be able to capture that 
disease in a cell line that can make every cell 
type in the body, and those cell types can be 
tested for their function in an immune-
defi  cient mouse. The technique then proven 
by the Jaenisch laboratory was via nuclear 
transfer of a body cell nucleus to an egg, and 
later isolating the inner 
cell mass of a developing 
blastocyst to make the 
cell line. I convinced my 
panel that if you go for-
ward with the research, 
oversee it, fund it well, 
make sure nobody’s do-
ing anything crazy, this 
could open up a whole 
new era in understanding 
human diseases like mul-
tiple sclerosis and Lou 
Gehrig’s Disease. It’s a powerful argu-
ment. And as long as you don’t use words 
like “histocompatibility” and “polymor-
phism,” most people will understand it.
How are you dealing with the NIH’s 
recent announcement of a ban on funding 
nuclear transfer–derived stem cell lines?
When President Obama announced that 
he was lifting Bush’s ban, I was there 
for the speech in the White House and 
later at the NIH. I was ecstatic. It was 
one of the greatest speeches of all time. 
So you can imagine how surprised I was 
when the NIH made their announcement 
that nuclear transfer research would not 
be supported.
There’s no scientifi  c reason not 
to push for nuclear transfer as a meth-
od. The only arguments against nucle-
ar transfer are religious or political, or 
are based on a personal moral code.
I’m president of the Interna-
tional Society for Stem Cell Re-
search, and we jointly decided to 
weigh in to say, “This is wrong; you 
should permit funding so long as it 
is done ethically and effi  ciently.” 
It’s falling on deaf ears right now, 
but it’s a start. It takes a while.
What are the biggest nonpolitical 
hurdles to this type of research?
The fi  rst, of course, is creating the lines with 
just a few eggs. Nobody is going to be happy 
if it takes 200 eggs to make a single cell line, 
because eggs come from people, by an inva-
sive procedure. The most important techni-
cal breakthrough will be doing effi  cient 
nuclear transfer with a few primate eggs to 
make stem cell lines. Or you could produce 
eggs from already developed embryonic 
stem cell lines. There are 
some people doing that, 
and it looks promising.
The real barriers 
will come as therapies 
emerge, when we have 
to fund clinical trials and 
companies that know 
what they’re doing. 
Many barriers will come 
up, but the biggest will 
be the fi  nancial ones.
How are your own efforts in this area 
coming along?
We’ve shown that, at least in mice, you can 
induce permanent transplantation tolerance 
by irradiating them and transplanting them 
with blood-forming stem cells from a donor. 
Then, whether the same day or a year later, 
you can transplant, for instance, a heart, or 
skin, or insulin-producing islets from the 
same donor. So we think that if we can estab-
lish that it’s safe and effective to transplant 
stem cells into people, and that the method 
induces tolerance, that it sets the stage for, 10 
or 20 years from now, using ES-derived liver 
precursors or blood forming stem cells, or 
whatever, for treating diseases. That’s truly 
regenerative medicine.
What types of disease are you working on?
At our institute, almost every one that’s a 
degenerative disease, where stem cells can 
regenerate the tissue. First we’re going 
for genetic defects of the blood-forming 
system, and then eventually for other ones.
Nine years ago, we isolated the 
human brain–forming stem cell. We know 
that in mice they can make virtually all of 
the brain cell types that are necessary for the 
therapies we’re doing. A company I started, 
called StemCells Inc., has already done 
phase I trials in children with an otherwise 
lethal neurodegenerative disease called 
Batten disease. Eventually it would be best 
to have the stem cells from the same donor, 
so that you wouldn’t have to immunosup-
press the kids while you’re treating them.
At some point, stem cell transplan-
tation could be used to treat autoimmune 
diseases and to get transplantation toler-
ance to grafts with no continuing immuno-
suppression. And because stem cells self-
renew, it’s a one-time treatment.
But in my own laboratory, I’d say 
the major emphasis right now is on fi  nd-
ing cancer-initiating cells from primary 
human cancer samples and testing anti-
bodies—which are made in mice bearing 
these cancer stem cell transplants—for 
their ability to ablate the tumor.
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A Botryllus colony has a primitive immune system that 
Weissman’s marine laboratory studies to understand 
the evolution of immunity.
“As long as 
you don’t use 
words like 
‘histocompatibility’ 
and 
‘polymorphism,’ 
most people will 
understand.”